Valuation: Satellos Bioscience Inc.

Market Cap 185M 163M 153M 140M 262M 17.76B 264M 1.84B 714M 9.04B 695M 680M 29.42B P/E 2026 *
-4.18x
P/E 2027 * -5.6x
Enterprise Value 83.45M 73.41M 69.2M 63.13M 118M 8.01B 119M 830M 322M 4.08B 313M 307M 13.27B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.63%
Yield 2026 *
-
Yield 2027 * -
1 day-1.38%
1 week-6.60%
Current month-6.46%
1 month-6.38%
3 months+26.51%
6 months+23.55%
Current year+53.66%
1 week 11.97
Extreme 11.97
13.1
1 month 11.97
Extreme 11.97
14.34
Current year 7.67
Extreme 7.67
18.98
1 year 7.56
Extreme 7.560003
18.98
3 years 3.48
Extreme 3.480001
18.98
5 years 2.58
Extreme 2.580001
20.28
10 years 2.58
Extreme 2.580001
22.8
Manager TitleAgeSince
Chief Executive Officer 70 28/02/2018
Chief Tech/Sci/R&D Officer - 30/04/2018
Director of Finance/CFO - 31/08/2023
Director TitleAgeSince
Chairman 59 30/06/2018
Director/Board Member 50 28/02/2018
Director/Board Member 70 30/06/2012
Date Insider Type Main position Quantity % Market Cap. Importance
18/08/26 Option

Director

10,608 0.0509%
18/08/26 Option

Director

10,608 0.0509%
18/08/26 Option

Director

10,608 0.0509%
Change 5-day change 1-year change 3-year change Capi.($)
-1.38%-6.60%+51.37%+111.28% 185M
-3.30%+1.19%+54.62%+104.15% 71.94B
+0.84%-3.40%+39.56%+76.40% 59.35B
+2.12%+5.26%+32.50%+21.28% 27.16B
-3.45%-2.62%-13.81%+353.30% 26.54B
-1.23%+2.13%+0.03%-4.86% 24.93B
+0.40%+0.88%+23.08%-9.56% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.17%-8.07%+499.10% 14.2B
-0.37%-1.15%+49.11%+164.27% 14.36B
Average -0.79%-0.76%+37.52%+164.11% 27.43B
Weighted average by Cap. -0.99%-0.25%+36.74%+131.34%

Financials

2026 *2027 *
Net sales - -
Net income -49.74M -43.75M -41.24M -37.63M -70.37M -4.77B -70.92M -495M -192M -2.43B -187M -183M -7.91B -61.15M -53.79M -50.7M -46.26M -86.51M -5.87B -87.19M -608M -236M -2.99B -230M -225M -9.72B
Net Debt -102M -89.37M -84.25M -76.86M -144M -9.75B -145M -1.01B -392M -4.96B -381M -373M -16.15B -119M -105M -98.67M -90.03M -168M -11.42B -170M -1.18B -459M -5.81B -447M -437M -18.92B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
25/09/26 CA$12.17 -1.38% 308
24/09/26 CA$12.34 +1.40% 9,615
23/09/26 CA$12.17 -4.02% 17,458
22/09/26 CA$12.68 -1.48% 5,730
21/09/26 CA$12.87 -1.23% 12,362
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.34CAD
Average target price
17.67CAD
Spread / Average Target
+43.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock